Literature DB >> 21063753

The phage therapy paradigm: prêt-à-porter or sur-mesure?

Jean-Paul Pirnay1, Daniel De Vos, Gilbert Verbeken, Maia Merabishvili, Nina Chanishvili, Mario Vaneechoutte, Martin Zizi, Geert Laire, Rob Lavigne, Isabelle Huys, Guy Van den Mooter, Angus Buckling, Laurent Debarbieux, Flavie Pouillot, Joana Azeredo, Elisabeth Kutter, Alain Dublanchet, Andrzej Górski, Revaz Adamia.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21063753     DOI： 10.1007/s11095-010-0313-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  10 in total

Review 1.  Bacteriophage therapy.

Authors:  A Sulakvelidze; Z Alavidze; J G Morris
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Antagonistic coevolution between a bacterium and a bacteriophage.

Authors:  Angus Buckling; Paul B Rainey
Journal:  Proc Biol Sci       Date:  2002-05-07       Impact factor: 5.349

3.  The influenza vaccine licensing process.

Authors:  J M Wood; R A Levandowski
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

4.  Old dogma, new tricks--21st Century phage therapy.

Authors:  Karl Thiel
Journal:  Nat Biotechnol       Date:  2004-01       Impact factor: 54.908

Review 5.  Population and evolutionary dynamics of phage therapy.

Authors:  Bruce R Levin; James J Bull
Journal:  Nat Rev Microbiol       Date:  2004-02       Impact factor: 60.633

Review 6.  Darwinian interventions: taming pathogens through evolutionary ecology.

Authors:  Paul David Williams
Journal:  Trends Parasitol       Date:  2009-12-25

7.  European regulatory conundrum of phage therapy.

Authors:  Gilbert Verbeken; Daniel De Vos; Mario Vaneechoutte; Maya Merabishvili; Martin Zizi; Jean-Paul Pirnay
Journal:  Future Microbiol       Date:  2007-10       Impact factor: 3.165

Review 8.  Phage therapy in clinical practice: treatment of human infections.

Authors:  Elizabeth Kutter; Daniel De Vos; Guram Gvasalia; Zemphira Alavidze; Lasha Gogokhia; Sarah Kuhl; Stephen T Abedon
Journal:  Curr Pharm Biotechnol       Date:  2010-01       Impact factor: 2.837

Review 9.  Bacteriophage therapy for the treatment of infections.

Authors:  Andrzej Górski; Ryszard Miedzybrodzki; Jan Borysowski; Beata Weber-Dabrowska; Małgorzata Lobocka; Wojciech Fortuna; Sławomir Letkiewicz; Michał Zimecki; Grace Filby
Journal:  Curr Opin Investig Drugs       Date:  2009-08

10.  Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.

Authors:  Maya Merabishvili; Jean-Paul Pirnay; Gilbert Verbeken; Nina Chanishvili; Marina Tediashvili; Nino Lashkhi; Thea Glonti; Victor Krylov; Jan Mast; Luc Van Parys; Rob Lavigne; Guido Volckaert; Wesley Mattheus; Gunther Verween; Peter De Corte; Thomas Rose; Serge Jennes; Martin Zizi; Daniel De Vos; Mario Vaneechoutte
Journal:  PLoS One       Date:  2009-03-20       Impact factor: 3.240
  10 in total
  89 in total

1.  Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Authors:  Alex R Hall; Daniel De Vos; Ville-Petri Friman; Jean-Paul Pirnay; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-01       Impact factor: 4.792

2.  Experimental evolution and bacterial resistance: (co)evolutionary costs and trade-offs as opportunities in phage therapy research.

Authors:  Pauline D Scanlan; Angus Buckling; Alex R Hall
Journal:  Bacteriophage       Date:  2015-05-21

3.  Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.

Authors:  Isabelle Huys; Jean-Paul Pirnay; Rob Lavigne; Serge Jennes; Daniel De Vos; Minne Casteels; Gilbert Verbeken
Journal:  EMBO Rep       Date:  2013-10-18       Impact factor: 8.807

4.  Experimental phage therapy of burn wound infection: difficult first steps.

Authors:  Thomas Rose; Gilbert Verbeken; Daniel De Vos; Maya Merabishvili; Mario Vaneechoutte; Rob Lavigne; Serge Jennes; Martin Zizi; Jean-Paul Pirnay
Journal:  Int J Burns Trauma       Date:  2014-10-26

5.  Coevolution with bacteriophages drives genome-wide host evolution and constrains the acquisition of abiotic-beneficial mutations.

Authors:  Pauline D Scanlan; Alex R Hall; Gordon Blackshields; Ville-P Friman; Michael R Davis; Joanna B Goldberg; Angus Buckling
Journal:  Mol Biol Evol       Date:  2015-02-12       Impact factor: 16.240

Review 6.  Ménage à trois in the human gut: interactions between host, bacteria and phages.

Authors:  Mohammadali Khan Mirzaei; Corinne F Maurice
Journal:  Nat Rev Microbiol       Date:  2017-05-02       Impact factor: 60.633

7.  Regulating phage therapy: The biological master file concept could help to overcome regulatory challenge of personalized medicines.

Authors:  Alan Fauconnier
Journal:  EMBO Rep       Date:  2017-01-12       Impact factor: 8.807

Review 8.  Phage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa Infections.

Authors:  Diana P Pires; Diana Vilas Boas; Sanna Sillankorva; Joana Azeredo
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

9.  New antibacterial microporous CaP materials loaded with phages for prophylactic treatment in bone surgery.

Authors:  Edwige Meurice; Emmanuelle Rguiti; Annie Brutel; Jean-Christophe Hornez; Anne Leriche; Michel Descamps; Franck Bouchart
Journal:  J Mater Sci Mater Med       Date:  2012-07-17       Impact factor: 3.896

10.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.